Mexico vs Nepal: Average cost of drugs for extensively drug-resistant tuberculosis
Mexico
3,500 constant 2022 US$
in 2024
Nepal
2,853 constant 2022 US$
in 2024
Mexico rank
19th
Nepal rank
21st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Mexico
- Nepal
How they compare
Mexico currently reports 3,500 constant 2022 US$ against 2,853 constant 2022 US$ in Nepal, a difference of 647 constant 2022 US$.
That makes Mexico's figure about 1.2 times Nepal's.
The two have swapped places 2 times across 7 shared years of data; in 2018 it was Mexico ahead.
Mexico ranks 19th and Nepal ranks 21st of 56 countries.
Mexico has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mexico | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,125 constant 2022 US$ | 2,811 constant 2022 US$ | 4,314 constant 2022 US$ | Mexico |
| 2020s | 4,063 constant 2022 US$ | 2,995 constant 2022 US$ | 1,069 constant 2022 US$ | Mexico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Mexico or Nepal?
- Mexico, at 3,500 constant 2022 US$ against 2,853 constant 2022 US$ in Nepal as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Mexico and Nepal?
- 647 constant 2022 US$, with Mexico ahead.
- How many years of comparable data are there for Mexico and Nepal?
- 7 years are reported by both, from 2018 to 2024.
- How do Mexico and Nepal rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Mexico ranks 19th and Nepal ranks 21st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.